Study On The Application Of Mifepristone And Leuprorelin Acetate After Hysteromyomectomy

Objective: To observe hysteromyoma patients’ sex hormone levels between lap aroscopic hysteromyomectomy alone and application of mifepristone and leuproreli n acetate in laparoscopic hysteromyomectomy, probe into the effects of mifepristone a nd leuprorelin acetate on the prevention of recurrence of uterine myomas after hysteromy omectomy.Method: A retrospective analysis of laparoscopic hysteromyomectomy patients, a total of 128 patients with complete clinical data, in Yancheng City Maternal and Child Health Care Hospital from January 2012 to December 2013. According to the patients’ intention all the patients are divided into three groups: laparoscopic hysteromyomectomy alone, application of mifepristone, leuprorelin acetate respectively in laparoscopic hysteromyomectomy 3 months adjuvant therapy. Record three groups of patients’ the follicular phase LH, FSH, E2 and P levels respectively, as well as recurrence rate after 6 and 12 months and drug adverse reaction.Results: 1. Mifepristone in the adjuvant therapy for 3 months, the sex hormone(FSH, LH, E2 and P) level(6.43±2.52IU/L, 7.85±3.73IU/L, 120.35±66.86ng/L, 0.35±0.22μg/L), and the control group(7.93±3.63IU/L, 11.34±5.13IU/L, 190.35±36.87ng/L, 0.63±0.20μg/L) were decreased and significant difference(P<0.01). Leuprorelin acetate in the adjuvant therapy for 3 months the sex hormone(FSH, LH, E2 and P) level(4.12±2.69IU/L, 5.35±3.93IU/L, 93.32±63.67ng/L, 0.23±0.16μg/L) became lower, significant difference(P<0.01). All the sex hormone levels of Leuprorelin acetate group were lower than that of mifepristone group, with statistical significance(P<0.05).2. Six months after surgery mifepristone group recurrence rate(2.32%), leuprorelin acetate group(2.22%) were lower than the control group(7.50%); the difference was statistically significant(P<0.01), while leuprorelin acetate group, compared with mifepristone group, has no obvious statistical significance(P>0.05). After 12 months mifepristone group recurrence rate(9.30%) was significantly lower than the control group(17.50%) with significant difference(P<0.01) whereas leuprorelin acetate group recurrence rate(4.44%) with significant difference(P<0.05).3. During the drug the patients of mifepristone group and leuprorelin acetate group could occur the digestive tract symptoms such as nausea, vomiting, loss of appetite, and other adverse reactions for example: hot flushes, dizziness, sleepiness, loss of libido, and the incidence rate was 25.58%, 28.88% respectively. Two groups of patients had mild adverse reactions, but they need no special processing if they quit the drugs.Conclusion: 1. After hysteromyomectomy using mifepristone adjuvant treatment for three months, it could effectively cut down the sex hormone, prevent recurrence within a year, less adverse reaction, safe and reliable curative effect, which was worthy of popularization and application.2. After hysteromyomectomy using leuprorelin acetate adjuvant treatment for three months, it could effectively cut down the sex hormone, less adverse reaction, safe and reliable curative effect, which was worthy of popularization and application.3. After hysteromyomectomy using leuprorelin acetate adjuvant treatment for three months compared with mifepristone adjuvant treatment for three months, can more significantly reduce the level of sex hormone, effectively cut down the recurrence rate within a year.